Newbury Pharmaceuticals Ab Stock Fundamentals
| NEWBRY Stock | 3.38 0.08 2.31% |
Newbury Pharmaceuticals AB fundamentals help investors to digest information that contributes to Newbury Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Newbury Stock. The fundamental analysis module provides a way to measure Newbury Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Newbury Pharmaceuticals stock.
Newbury |
Newbury Pharmaceuticals AB Company Return On Equity Analysis
Newbury Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Newbury Pharmaceuticals Return On Equity | -0.34 |
Most of Newbury Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Newbury Pharmaceuticals AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Newbury Pharmaceuticals AB has a Return On Equity of -0.3403. This is 98.58% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers-Specialty & Generic industry. The return on equity for all Sweden stocks is 9.77% higher than that of the company.
Newbury Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Newbury Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Newbury Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Newbury Pharmaceuticals competition to find correlations between indicators driving Newbury Pharmaceuticals's intrinsic value. More Info.Newbury Pharmaceuticals AB is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Newbury Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Newbury Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Newbury Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Newbury Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Newbury Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Newbury Pharmaceuticals by comparing valuation metrics of similar companies.Newbury Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Newbury Fundamentals
| Return On Equity | -0.34 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.89) % | |||
| Operating Margin | (2.75) % | |||
| Current Valuation | 96.57 M | |||
| Shares Outstanding | 19.52 M | |||
| Shares Owned By Insiders | 78.64 % | |||
| Shares Owned By Institutions | 6.72 % | |||
| Price To Book | 1.86 X | |||
| Price To Sales | 25.09 X | |||
| Revenue | 5.77 M | |||
| Gross Profit | 1.56 M | |||
| EBITDA | (15.74 M) | |||
| Book Value Per Share | 3.24 X | |||
| Target Price | 8.5 | |||
| Market Capitalization | 110.88 M | |||
| Total Asset | 86.91 M | |||
| Net Asset | 86.91 M |
About Newbury Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Newbury Pharmaceuticals AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Newbury Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Newbury Pharmaceuticals AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Newbury Stock
Newbury Pharmaceuticals financial ratios help investors to determine whether Newbury Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Newbury with respect to the benefits of owning Newbury Pharmaceuticals security.